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Abstract
Accumulating lines of experimental evidence have revealed that hypoxia-inducible factors, HIF-1a and HIF-2a, are key regulators of the adapta-
tion of cancer- and metastasis-initiating cells and their differentiated progenies to oxygen and nutrient deprivation during cancer progression
under normoxic and hypoxic conditions. Particularly, the sustained stimulation of epidermal growth factor receptor (EGFR), insulin-like growth
factor-1 receptor (IGF-1R), stem cell factor (SCF) receptor KIT, transforming growth factor-b receptors (TGF-bRs) and Notch and their down-
stream signalling elements such as phosphatidylinositol 3′-kinase (PI3K)/Akt/molecular target of rapamycin (mTOR) may lead to an enhanced
activity of HIFs. Moreover, the up-regulation of HIFs in cancer cells may also occur in the hypoxic intratumoral regions formed within primary
and secondary neoplasms as well as in leukaemic cells and metastatic prostate and breast cancer cells homing in the hypoxic endosteal niche
of bone marrow. The activated HIFs may induce the expression of numerous gene products such as induced pluripotency-associated transcrip-
tion factors (Oct-3/4, Nanog and Sox-2), glycolysis- and epithelial-mesenchymal transition (EMT) programme-associated molecules, including
CXC chemokine receptor 4 (CXCR4), snail and twist, microRNAs and angiogenic factors such as vascular endothelial growth factor (VEGF).
These gene products in turn can play critical roles for high self-renewal ability, survival, altered energy metabolism, invasion and metastases of
cancer cells, angiogenic switch and treatment resistance. Consequently, the targeting of HIF signalling network and altered metabolic pathways
represents new promising strategies to eradicate the total mass of cancer cells and improve the efficacy of current therapies against aggressive
and metastatic cancers and prevent disease relapse.
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Introduction
Recent advances in cancer research have indicated that the enhanced
expression and activation of hypoxia-inducible factors (HIFs)
frequently occur in cancer cells during cancer progression and is
associated with their acquisition of a more malignant behaviour, treat-
ment resistance and poor outcome of cancer patients (Fig. 1) [1–12].
Particularly, responses of cancer cells to environmental stress as
observed for their normal counterparts generally implicate the induc-
tion of HIFs [1, 3–5, 9–16]. HIF transcription factors of the basic
helix-loop-helix (bHLH)/PAS family include HIF-1a that is differently
expressed in most tissues and HIF-2a which shows a more restricted
tissue expression pattern in various locations, including kidneys,
brain, lungs, liver, gastrointestinal tract, pancreas and heart [1, 2, 17,
18, 18–20]. The regulation of the cellular stability and activity of HIF-
1a and HIF-2a in normal cells and cancer cells is highly dependent on
oxygen supply (Figs 1–4) [3, 18, 21, 22]. In fact, oxygen-sensitive
HIF-a proteins are generally hydroxylated by prolyl hydroxylase
domain (PHD) proteins under normoxic conditions [21, 23]. This
molecular event results in the interaction of HIF-a with Von Hippel-
Lindau (VHL) tumour suppressor gene product, which is a compo-
nent of the protein complex possessing a ubiquitin ligase E3 activity,
that targets the HIF-a subunit for polyubiquitylation and subsequent
proteasomal degradation (Fig. 3) [22, 23]. In contrast, the HIF-a
subunit does not interact with the VHL protein in the presence of low
oxygen levels and translocates to the nucleus where it forms a hetero-
dimer with the constitutively expressed HIF-b partner subunit, also
designated as aryl hydrocarbon receptor nuclear translocator (ARNT)
that specifically binds to hypoxia-responsive elements (HREs) found
in target gene promoters (Fig. 3) [3, 24].
In addition to the up-regulation of HIF activity under low oxygen
tension, the stability and activation of HIF-1a and HIF-2a in cancer
cells may also be differently regulated through the sustained stimula-
tion of different growth factor and cytokine pathways and oxidative
Fig. 1 Cellular events and signalling elements involved in the regulation of the stabilization and activation of hypoxia-inducible factors. The increase
in the stability and activation of HIFs, HIF-1a and HIF-2a, in cancer cells including cancer stem/progenitor cells, which may be induced via different
growth factor and cytokine pathways under normoxic and hypoxic conditions, hypoxic microenvironment and inflammation are illustrated. The
potential cellular signalling elements modulated through the up-regulation of HIFs and which can contribute to high self-renewal, altered glycolytic
metabolism, invasion, metastases, treatment resistance and disease relapse are also indicated. BCRP/ABCG2: breast cancer resistance protein; CAIX:
carbonic anhydrase; EGFR: epidermal growth factor receptor; GLUT: glucose transporter; IL-6: interleukin-6; MAPK: mitogen-activated protein kinase;
MCT-4: monocarboxylate transporter-4; MIC-1: macrophage inhibitory cytokine-1; MMPs: metalloproteinases; mTOR: molecular target of rapamycin;
NF-jB: nuclear factor-jB; RTK: receptor tyrosine kinase; PI3K: phosphatidylinositol 30-kinase; PGK1: phosphoglycerate kinase 1; PKM: pyruvate
kinase M; P-gp: P-glycoprotein; ROS: reactive oxygen species; TGF-b: transforming growth factor-b; TNF-a: tumour necrosis factor-a; STAT3: signal
transducer and activator of transcription 3; VEGF: vascular endothelial growth factor.
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stress under normoxic and hypoxic conditions (Figs 1 and 3)
[25–33]. The growth factor signalling elements include different
receptor tyrosine kinases (RTKs), such as epidermal growth factor
receptor (EGFR/erbB1), HER2/erbB2/Neu, insulin-like growth factor-1
receptor (IGF-1R), stem cell factor (SCF)/KIT receptor, Notch, inter-
leukin-6/IL-6R receptor and transforming growth factor-b/TGF-bR
Fig. 2 Proposed model of malignant transforming events associated with cancer progression and metastases driving hypoxia and enhanced expres-
sion of HIFs in cancer stem/progenitor cells. Genetic and epigenetic alterations occurring in tissue-resident adult stem/progenitor cells during intense
injury, oxidative stress, inflammation and/or ageing may result in their malignant transformation into tumourigenic cancer stem/progenitor cells also
designated cancer-initiating cells that are able to generate the bulk mass of heterogeneous and differentiated cancer cells within tumour. The
scheme also shows the potential localization of clusters of cancer stem/progenitor cells expressing HIFs at the hypoxic region near a necrotic areas
and invasive front of the primary tumour. The enhanced expression of HIFs in highly tumourigenic cancer stem/progenitor cells and their differenti-
ated progenies, which may be induced under hypoxia or sustained activation of growth factor pathways and PI3K/Akt/mTOR under normoxic and
hypoxic conditions, may promote the EMT programme, altered metabolic pathways and re-expression of stem cell-like markers such as Oct-3/4,
Sox-2 and Nanog and pro-angiogenic factor VEGF. These molecular transforming events in turn may contribute to the acquisition of a more malig-
nant behaviour and migratory ability by cancer cells and tumour neovascularization. Moreover, bi-directional cross-talks between cancer cells and
stromal myofibroblasts found within their local tumour microenvironment also may promote their gain of more aggressive phenotypes. Hence,
highly tumourigenic and migratory cancer stem/progenitor cells with stem cell-like properties that survive under stressful conditions, including low
oxygen tension and nutrient deprivation, during primary cancer progression and reach the invasive front of primary tumour can be involved in dis-
semination and metastatic spread at near lymph nodes and distant tissues. The disseminated cancer stem/progenitor cells that are able to survive in
their novel microenvironment prevalent at metastatic sites can give rise to the total mass of differentiated cancer cells forming secondary tumours.
The preferential migration of cancer cells to pre-metastatic niches induced by different soluble factors released from primary tumour and bone mar-
row-derived cells (BMDCs) at distant sites is also illustrated.
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receptors [25–39]. These tumourigenic pathways may cooperate to
stimulate different downstream signalling elements, including phos-
phatidylinositol 3′-kinase (PI3K)/Akt/molecular target of rapamycin
(mTOR), Ras/mitogen-activated kinase (MEK)/extracellular signal-
regulated kinase (ERK), nuclear factor-kappaB (NF-jB) and signal
transducer and activator of transcription 3 (STAT3) pathways that
in turn up-regulate the expression and/or stability of HIF-a subunit
[25–40]. Also, inactivation of tumour suppressor proteins such as
pVHL, phosphatase tensin deleted on chromosome 10 (PTEN) and
p53 in cancer cells may impair HIF degradation and/or enhanced
PI3K/Akt activation and lead to HIF-a protein accumulation and
increased expression of many HIF-regulated genes under normoxic
and hypoxic conditions [1, 22, 28, 38, 41, 42]. Hence, HIF transcrip-
tion factors can activate the transcription of numerous gene products
that contribute to the malignant reprogramming of cancer cells during
cancer progression and metastases and tumour angiogenic switch
(Figs 1 and 3) [4, 25–33, 36, 37, 39, 41–44].
Importantly, recent findings have also indicated that HIF-1a and
HIF-2a play critical roles for the gain of more malignant phenotypes
by highly tumourigenic cancer stem/progenitor cells endowed with
stem cell-like properties also designated as cancer-, tumour-, and
metastasis-initiating cells that are able to generate the bulk mass of
heterogeneous and differentiated cancer cells within tumours and
which are involved in primary cancer progression, metastases, resis-
tance to current cancer therapies and disease relapse [14, 45–53].
Thus, the complete eradication of the total mass of tumour cells,
including hypoxic and normoxic cancer stem/progenitor cells and
their differentiated progenies, by targeting the HIF signalling network
might be crucial to improve current cancer therapies and prevent
disease relapse. New therapeutic strategies such as guanine-rich
oligodeoxynucleotides (G-rich ODNs), chemical compounds and
chemotherapeutic drugs that target HIF-1a and/or HIF-2a proteins
and repress the expression of their target genes in various cancer
cells have been shown to counteract primary cancer progression and
Fig. 3 Scheme showing the potential molecular events induced in cancer cells in the hypoxic tumour microenvironment. The intracellular conse-
quences of decreased oxygen level (hypoxia) in cancer cells including the switch of mitochondrial oxidative phosphorylation to anaerobic glycolysis
and enhanced nuclear translocation of HIF-a subunit are illustrated. The enhanced stabilization and activation of HIF-1a and HIF-2a and their forma-
tion of nuclear heterodimers with HIF-b receptor in cancer cells under hypoxia that in turn may result in the transcriptional activation of numerous
gene products involved in anaerobic glycolysis, pH regulation, self-renewal, survival and induction of angiogenic switch and metastases are indi-
cated. The enhanced cellular accumulation and activation of HIF-a protein subunit which may be induced through the stimulation of different recep-
tor tyrosine kinases (RTKs) in cancer cells under normoxic and hypoxic conditions are also illustrated. Particularly, the stimulation of RTKs may
lead to the sustained activation of phosphatidylinositol 3′-kinase (PI3K)/Akt/molecular target of rapamycin (mTOR) pathway that in turn may induce
the translational machinery and HIF protein synthesis and/or enhanced stabilization of HIF-a subunit. Moreover, the activation of RTKs may result in
the stimulation of nuclear factor-kappaB (NF-jB) that in turn can induce the transcriptional up-regulation of HIFs. ABCG2/BCRP: breast cancer resis-
tance protein; CAIX: carbonic anhydrase IX; COX-2: clyooxygenase-2; ECM: extracellular matrix; FOXO3A: forehead 3A; GLUT: glucose transporter;
HIFs: hypoxia-inducible factors; IAP: inhibitor of apoptosis protein; IL-6: interleukin-6; MAPK: mitogen-activated protein kinase; MCT: monocarboxy-
late transporter; MIC-1: macrophage inhibitory cytokine-1; MMPs: matrix metalloproteinases; pHe: extracellular pH; pHi: intracellular pH; PGK1:
phosphoglycerate kinase 1; PKM: pyruvate kinase M; VEGF: vascular endothelial growth factor.
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metastases at distant sites, and reverse treatment resistance under
normoxic and hypoxic conditions (Tables 1 and 2) [11, 39, 44, 54–
66]. In this matter, we review recent findings indicating pivotal roles
of HIF-1a and HIF-2a in the modulation of stemness properties and
altered metabolic pathways of cancer stem/progenitor cells and their
differentiated progenies during the development of diverse aggressive
Fig. 4 Proposed model of potential transforming events occurring in
hypoxic cancer cells during epithelial cancer progression and bone
metastasis. The up-regulated expression levels of stem cell-like pheno-
types, HIFs, CXC chemokine receptor (CXCR4) and occurrence of the
EMT programme in prostate or breast cancer cells within the hypoxic
region at the invasive front of the primary tumour may lead to their
invasion and dissemination through the peripheral circulation and hom-
ing at distant metastatic sites. More specifically, circulating prostate or
breast cancer cells expressing high level of CXCR4 can preferentially
disseminate and home to specific metastatic sites such as bones at
least in part through the chemoattractant gradient formed by stromal
cell-derived factor-1 (SDF-1) released by endothelial cells. The hypoxia-
adapted prostate or breast cancer cells may compete with long-term
haematopoietic stem cells (LT-HSCs) to occupy the hypoxic endosteal
niche within BM and survive under a dormant state for a short or long
period of time. The activation of dormant prostate or breast cancer cells
may occur through the release of different growth factors and cytokines
by cancer cells and stromal host cells under specific microenvironmen-
tal conditions. The activated prostate or breast cancer cells can give rise
to the total tumour cell mass and skeletal metastasis formation. The
bone metastases of prostate cancer cells are predominantly associated
with the formation of osteoblastic lesions (bone formation), whereas
bone metastases of breast cancer cells are generally related with the
formation of osteolytic lesions (bone destruction).
Table 1 Potential therapeutic strategies targeting altered growth
factor and intracellular elements in normoxic and hypoxic cancer-
and metastasis-initiating cells and their differentiated progenies
Molecular target Name of inhibitory agent
Hypoxia-activated pro-drug
Hypoxic cancer cells TH-302
Growth factor signalling elements
EGFR (erbB1) Anti-EGFR mAb (cetuximab or
IMC-C225 (Erbitux®)*,
panitumumab (Vectibix®)*,
mAb-C225); TKI (gefitinib
(Iressa®)*, erlotinib (Tarceva®)*,
AG1478)
HER-2 (erbB2) Anti-HER-2 mAb
(trastuzumab (Herceptin®)*)
IGF-1R Anti-IGF-1R mAb (robatumumab
or R1507); TKI (NVP-AEW541,
BMS-536924)
TGF-bRI SD-208
KIT Imatinib mesylate (Gleevec®)*,
dasatinib (Sprycel®)*
nilotinib or
AMN107 (Tasigna®)*,
bafetinib (INNO-406)
Notch c-secretase inhibitor
(DAPT, MK-0752, GSI-18)
Nodal/Cripto Anti-Cripto mAb, LEFTY
Wnt/b-catenin Anti-Wnt antibody, AV65, WIF-1
CXCR4 Anti-CXCR4 mAb, CXCR4
antagonist (plerixafor or
AMD3100 (Mozobil®)*)
VEGF Anti-VEGF mAb
(bevacizumab (Avastin®)*)
VEGFR-2 Anti-VEGFR-2 mAb
(ramucirumab or IMC-1121B,
DC101 or IMC-1C11)
VEGFR-2, EGFR, RET-TKI MKI (Vandetanib or ZD6474)
VEGFRs, PDGFRs, KIT MKI [Sunitinib (Sutent®)*,
Axitinib or
AG-013736 (Inlyta®)*]
VEGFR-2 and -3, PDGFRs,
KIT, B-Raf, C-Raf
MKI (Sorafenib (Nexavar®)*)
VEGFRs, PDGFRs, FGFR-1,
FGFR-3, KIT, Itk, Lck
and c-Fms
MKI (Pazopanib (Votrient®)*)
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and recurrent cancers. The emphasis is on the functions of HIFs
during leukaemogenesis and the development of glioblastoma
multiforme, melanoma and prostate, breast and pancreatic cancers
and novel targeted therapies directed against HIFs and altered meta-
bolic pathways, including glycolysis, lipogenesis and autophagy.
Critical functions of HIFs in the
acquisition of more malignant
phenotypes and behaviour by cancer-
and metastasis-initiating cells and
their differentiated progenies
A growing body of experimental evidence has indicated that most
human cancers may originate from the accumulation of different
genetic and epigenetic alterations in tissue-resident adult stem cells
and/or their early progenitors with stem cell-like properties during the
lifespan resulting in their malignant transformation into cancer stem/
progenitor cells [45, 47, 49, 52, 53, 67–73]. In support of this, cancer
cells expressing stem cell-like markers and endowed with a high self-
renewal ability and aberrant differentiation potential have been identi-
fied and isolated from primary neoplasms, peripheral circulation and
metastatic tissue specimens [45, 53, 68, 71, 73–83]. Cancer types
harbouring a cancer stem/progenitor cell subpopulation include
Table 1. Continued
Molecular target Name of inhibitory agent
Intracellular signalling elements
HIFs YC-1, P276-00, P3155,
NSC-134754,
PX-478, KCN1 G-rich ODNs
(JG243 and JG244),
anthracyclins,
2-methoxyestradiol,
echinomycin, Rakicidin A
PI3K LY294002, Wortmannin
mTOR Everolimus or RAD001
(Afinitor, Zortress or
Certican®)*, temsirolimus
or CCI-779 (Torisel®)*,
sirolimus or rapamycin
(Rapamune®)*
PI3K/mTOR PI-103, NVP-BEZ235
Ras S-trans trans-farnesylthiosalicylic
acid
NF-jB bortezomib (Velcade®)*,
sulphasalazine (Azulfidine®)*,
salinosporamides A (NPI-0052),
parthenolide IkBa inhibitor
(PS-341)
STAT3 G-rich ODN (T40214)
COX-2 Etodolax (Lodine SR or
Eccoxolac®)*, NS-396
Bcl-2 and/or Bcl-xL AS (oblimersen sodium
(Genasense®)*), ABT-263
BCR-ABL Imatinib mesylate (Gleevec®)*,
dasatinib (Sprycel®)*
nilotinib or
AMN107 (Tasigna®)*,
bafetinib (INNO-406)
*Trade name of Food and Drug Administration (FDA) approved drug
for treating specific cancer(s) and/or other disorder(s).
c-Fms: transmembrane glycoprotein receptor tyrosine kinase; AS:
antisense oligonucleotide; COX-2: clyooxygenase-2; CXCR4: CXC
chemokine receptor 4; DAPT: N-(N-3,5-difluorophenacetyl)-L-alanyl]-
S-phenylglycine t-butyl ester; EGFR: epidermal growth factor receptor;
G-rich ODNs: guanine-rich oligodeoxynucleotides; FGFR: fibroblast
growth factor receptor; IGF-RI: insulin-like growth factor-1 receptor;
Itk: interleukin-2 receptor inducible T-cell kinase; KCN1: 3,4-dimeth-
oxy-N-[(2,2-dimethyl-2H-chromen-6-yl)methyl]-N-phenylbenzenesulpf-
onamide; Lek: leucocyte-specific protein tyrosine kinase; mAb:
monoclonal antibody; MKI: multi-targeted kinase inhibitor; NF-jB:
nuclear factor-kappaB; PI3K: phosphatidylinositol 3′-kinase; STAT3:
signal transducer and activator of transcription 3; TGF-bR: transform-
ing growth factor-b receptor; TKI: tyrosine kinase inhibitor; VEGF:
vascular growth factor; Wnt: Wingless ligand.
Table 2 Potential therapeutic strategies targeting altered metabolic
and pH regulatory signalling pathways in normoxic and hypoxic
cancer- and metastasis-initiating cells and their differentiated
progenies
Molecular therapeutic target Name of inhibitory agent
Altered metabolic signalling elements
Glucose transporters 2-deoxy-D-glucose
Hexokinase-2 Lonidamine
Glyoxalase-1 S-p-bromobenzylglutathione
FASN Orlistat, cerulenin, C75, resveratrol
Monoacylglycerol lipase JZL184
Autophagy Bafilomycin A1, 3-methyladenine,
chloroquine (Aralen®)*,
hydrochloroquine (Plaquenil®)*
pH regulatory signalling element
CAIX Anti-CAIX mAbs (M75 and G250),
glycosyl coumarins
(GC-204 and GC-205),
sulphonamides (CAI17,
ureido-sulphonamide, U-104)
*Trade name of Food and Drug Administration (FDA) approved drug.
CAIX: carbonic anhydrase IX; FASN: fatty acid synthase.
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leukaemias, brain tumours, melanomas and various epithelial cancers
such as lung, liver, gastrointestinal, colorectal, pancreatic, breast,
ovarian and prostate cancers [45, 47, 53, 68, 71, 73–77, 79, 80, 82–
86]. It has been shown that cancer stem/progenitor cells can give rise
to the total mass of heterogeneous and differentiated cancer cells
within primary and secondary tumours and play key roles for inva-
sion, metastases at regional and distant tissues as well as tumour
angiogenesis [45, 47, 49, 52, 53, 68, 69, 71, 73–77, 79, 82, 83, 87–
89]. New findings have also indicated that cancer- and metastasis-ini-
tiating cells with stem cell-like features typically display a higher
resistance than the bulk mass of differentiated cancer cells to oxygen
and nutrient deprivation and current anti-hormonal, radiation therapy
and chemotherapy, and thereby they can be responsible for disease
relapse [6, 12, 49, 51–53, 56, 73–77, 79, 82, 83, 88, 90–96].
Recently, the cancer stem cell hypothesis has also been reviewed
to consider the complexity of molecular transforming events that may
occur in these immature cancer cells and their differentiated proge-
nies as well as their local microenvironment under normoxic and hyp-
oxic conditions during cancer development [6, 47, 49, 82, 83]. Based
on the cancer stem cell concept, cancer heterogeneity may be attrib-
uted to the differences between tissue-resident stem/progenitor cell
types at the origin of particular cancer subtypes as well as progres-
sive changes in the number and phenotypes of these immature can-
cer cells and their differentiated progenies and their local
microenvironment during disease progression and after treatment ini-
tiation (Fig. 2) [7, 47, 82, 83, 97]. In this regard, rapidly growing
tumours are typically characterized by disorganized vasculature with
an abnormal leaky and tortuous structure [5–7, 98–100]. These rap-
idly growing tumours also exhibit hypoxic intratumoral regions that
did not supply sufficient oxygen and nutrients to cells and require a
high adaptation of cancer cells for their survival [5–7, 98–100]. It has
been shown that changes in the local microenvironment of cancer
stem/progenitor cells and their progenies, including the induction of
hypoxic intratumoral regions within poorly vascularized tumours,
may result in alterations of different gene products that contribute to
their acquisition of more aggressive phenotypes and survival advanta-
ges [1, 7, 14, 46, 48, 50, 51, 66, 89, 98–104]. More specifically, it
has been observed that hypoxia and enhanced expression and activity
of HIF-1a and HIF-2a in cancer stem/progenitor cells and their proge-
nies frequently occur during disease progression and metastases and
may result in the up-regulation of different stemness gene products
and survival signalling elements [6, 14, 48, 50, 90, 94, 99, 102, 104,
105]. The altered gene products modulated by HIFs comprise the regu-
lators of induced pluripotency (octamer-binding transcription factor
Oct-3/4, Sox-2 and Nanog), epithelial-mesenchymal transition (EMT)
programme (EGFR, CXCR4, snail and twist), glucose transporters
(GLUT-1/2) involved in the glucose uptake, altered metabolic pathways
such as glycolytic enzymes, microRNAs (miRNAs) and drug resis-
tance-associated molecules (ABCB2, Bcl-2, Bcl-xL, survivin and macro-
phage inhibitory cytokine-1 ‘MIC-1’; Figs 1–3) [4, 14, 22, 25, 51, 99,
100, 106–110]. These HIF-induced signalling elements may provide
critical functions for high self-renewal capacity, energy supply through
enhanced aerobic and anaerobic glycolysis, invasion, metastases and
treatment resistance of cancer- and metastasis-initiating cells and their
differentiated progenies [4, 14, 22, 25, 99, 100, 106–112].
In addition, among other important gene products modulated by
HIF-1a, monocarboxylate transporter-4 (MCT-4) and carbonic anhy-
drase IX (CAIX) are often overexpressed in several cancer types as
compared with normal tissues and involved in the pH regulatory sys-
tem of hypoxic cancer cells characterized by a high rate of glycolytic
metabolism and production of acidic metabolites such as lactic and
carbonic acids (Fig. 3) [113–116]. More specifically, MCT-4 can con-
tribute to the export of lactate into extracellular space of cancer cells
[115, 116]. Furthermore, CAIX is a dimeric transmembrane metal-
loenzyme that catalyses the rapid interconversion of carbon dioxide
(CO2) molecules to bicarbonate (HCO3
#) and protons (H+) in the
extracellular space of hypoxic cancer cells [113–115]. Hence,
bicarbonate generated by CAIX may be subsequently transported by
different bicarbonate transporters such as sodium bicarbonate
co-transporters into cancer cells, and thereby plays key roles for the
maintenance of intracellular pH (pHi) necessary for the survival and
growth of cancer cells [113–115]. Also, the generation of protons
through the hydration of carbon dioxide by CAIX and accumulation of
acidic metabolites in the local microenvironment of cancer cells may
contribute to the acidification of extracellular pH (pHe) that favours
the normal cell death, degradation of extracellular matrix (ECM), stro-
mal invasion and metastases of cancer cells (Fig. 3) [113–115]. In
addition, the induction of tumour angiogenesis by HIFs through the
up-regulated expression of pro-angiogenic factors such as vascular
endothelial growth factor (VEGF) in cancer stem/progenitor cells and
their differentiated progenies may also promote the tumour growth
and formation of invasive and metastatic cancers (Figs 1–3) [25, 35,
39, 106, 117–119].
Although a highly structural homology exists between HIF-1a and
HIF-2a, these transcription factors may also be differently regulated
and transactivate common and unique targeted gene products in a
cancer cell-dependent manner under normoxic and hypoxic condi-
tions (Fig. 3) [16, 20, 24, 89, 106, 107, 117, 120–125]. Particularly,
the differences between the tissue expression pattern and transactiva-
tion domains of HIF-1a and HIF-2a proteins and their recruitment of
different transcriptional factors acting co-activator or co-repressor
may lead to their activation of specific gene subsets in normal and
cancer cells [20, 23, 24, 106, 122, 123]. The transcription factors that
can cooperate with HIFs include different histone acetyl transferase
(HAT) co-activators such as CREB-binding protein (CBP)/adenovirus
E1A-binding protein p300 (p300) and proteins in steroid receptor co-
activators (SRCs)/p160 family such as SRC-1 [20, 23, 24, 106, 122,
123]. In general, HIF-1a may specifically induce the enhanced expres-
sion of CAIX, lysyl oxidase (LOX) and glycolytic enzymes such as
hexokinase-2, aldolase A, phosphoglycerate kinase 1 (PGK1) and
pyruvate kinase M (PKM), whereas HIF-2a appears to preferentially
up-regulate the gene products including TGF-a, Myc, cyclin D1 and
embryonic stem cell-like markers such as Oct-3/4, Sox-2 and/or
Nanog in cancer cells under normoxic and hypoxic conditions (Figs 1
and 3) [16, 106, 107, 117, 120, 121, 124–127]. In this regard, we
review the molecular mechanisms controlling the expression levels
and specific functions of HIF-1a and HIF-2a and their downstream
signalling elements during initiation and progression of leukaemias,
glioblastoma multiforme, melanoma and epithelial cancers such as
prostate, breast and pancreatic cancers.
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Functions of HIF-1a in leukaemic
stem/progenitor cells and their
differentiated progenies and novel
targeted therapies
Numerous investigations have revealed that leukaemias may originate
from the accumulation of genetic and/or epigenetic alterations occur-
ring in haematopoietic stem cells (HSCs), precancerous-LSCs (pre-
LSCs) or more committed myeloid progenitor cells endowed with a
high self-renewal ability and aberrant differentiation potential [45, 68,
69, 71, 87]. Importantly, recent lines of experimental evidence have
also indicated that LSCs and their early progenitors may occupy the
endosteal and perivascular niches of normal haematopoietic stem/
progenitor cells (HSCs and HPCs) [45, 55, 72, 87, 128, 129]. More
particularly, the homing of primitive LSCs in the hypoxic microenvi-
ronment in BM endosteum, which may lead to an up-regulation of
HIF-1a and metabolic adaptation of these immature leukaemic cells
to low oxygen supply and glucose availability as observed for their
normal counterpart, long-term HSCs (LT-HSCs), may contribute to
their survival and treatment resistance [6, 55, 56, 69, 90, 128–130].
In fact, the homing of LSCs under a quiescent state in the more hyp-
oxic endosteal region of BM may allow these immature leukaemic
cells to exist in a low cycling state that protects them from oxidative
stress, DNA damages and cell death stimuli induced by cytotoxic
agents [45, 87, 90, 94, 129].
More particularly, chronic myeloid leukaemia (CML) is a clonal
disorder which is often accompanied by a chromosomal translocation
resulting in a shortened chromosome 22, designated the Philadelphia
(Ph+) chromosome in HSCs [68–70]. This molecular event generates
a chimeric BCR-ABL fusion oncoprotein endowed with a constitutive
tyrosine kinase activity in LSCs in the initial chronic phase of CML [68
–70]. Typically, this initial chronic phase of CML progresses to an
accelerated phase mediated through the occurrence of further onco-
genic events in LSCs, that ultimately leads to the terminal phase of
CML, designated as blast-crisis (Bc)-CML [68–70, 131]. Also, an
increase in the b-catenin level may occur in the granulocyte-macro-
phage progenitors when patients reach a later stage of Bc-CML and
result in their acquisition of an enhanced self-renewal capacity and
leukaemic potential [68, 130]. In this matter, it has been shown that
tyrosine kinase inhibitors (TKIs) such as imatinib mesylate (IM) or
the second generation of drugs, including dasatinib, nilotinib and baf-
etinib (INNO-406), targeting the BCR-ABL fusion protein in prolifera-
tive leukaemic cells are highly effective for treating patients with
chronic phase CMLs and Ph-positive acute lymphoid leukaemias
(ALLs) [6, 56, 91–93, 130, 132]. Unfortunately, CML cells can exhibit
BCR-ABL kinase-dependent and -independent mechanisms of resis-
tance to these TKIs [6, 56, 91–93, 130]. Moreover, these TKIs did not
appear to eradicate the total mass of leukaemic cells including primi-
tive and quiescent BCR-ABL LSCs with a high self-renewal potential
[6, 56, 91–93, 130]. Consequently, the persistence of LSCs in the
hypoxic endosteal niche of BM after cessation of TKI therapy may
result in disease relapse and require a long-life treatment with TKIs
for the survival of CML patients [6, 56, 91–93, 130]. Importantly, it
has been observed that human BCR-ABL+ CML-LSCs engrafted in the
BM of immunodeficient mice and survived under severe hypoxia
(<1.3% oxygen) along the endosteum [90]. It has also been shown
that BCR-ABL fusion oncoprotein can up-regulated the expression
levels of HIF-1a and its target genes via the stimulation of PI3K/Akt/
mTOR pathway in the murine BCR-ABL+ Ba/F3 leukaemic cell line and
contribute to their survival [55]. Moreover, hypoxia and HIF-1a in turn
can promote the selection of LSCs in CML that are refractory to IM
and bortezomib [90, 94, 133]. More specifically, it has been reported
that hypoxia-adapted BCR-ABL+ leukaemic cell lines obtained after
long-term culture under 1% oxygen level exhibited stem cell-like
properties, a great number of leukaemic cells in the side population
(SP) and under a dormant state, high resistance to TKIs including IM,
INNO-406 or dasatinib, enhanced expression level of b-catenin and
glyoxalase-1 activity and transplantation efficacy [90]. Hence, these
data suggest that BCR-ABL induced–enhanced expression of HIF-1a
in CML cells, including CML-LSCs, may contribute to their quiescence
and survival in the hypoxic endosteal niche of HSCs in BM after treat-
ment initiation and disease relapse.
Of therapeutic interest, the deletion of HIF-1a in a mouse model
of human CML has been observed to inhibit the cell cycle progression
and induce the apoptosis via an induction of p16INK4A and p19ARF
tumour suppressor proteins in LSCs [55]. Moreover, it has been
shown that a natural product of Micromonospora strain designated
as Rakicidin A, which acts as a hypoxia-selective cytotoxin, was effec-
tive at inducing the apoptotic death of TKI-resistant and hypoxia-
adapted BCR-ABL+ CML cells endowed with stem cell-like properties
maintained in suspension under low-oxygen conditions for more than
6 months [56]. The combined use of Rakicidin A plus IM or dasatinib
also resulted in synergistic cytotoxic effects on hypoxia-adapted BCR-
ABL+ CML cells [56]. In the same way, it has also been observed that
the down-regulation of HIF-1a by small hairpin RNA (shRNA) or using
a HIF-1a inhibitor, echinomycin eradicated mouse lymphoma-initiat-
ing cells and human acute myeloid leukaemia (AML)-LSCs in both
in vitro colony formation assays and in vivo mouse models, whereas
normal HSCs were 100-fold less sensitive to echinomycin than
lymphoma CSCs in vitro [134].
On the other hand, other molecular mechanisms that may contrib-
ute to the resistance of LSCs or their early progenitors also include
the elevated expression of b-catenin and enhanced glycolytic metabo-
lism and autophagy under normoxic and hypoxic conditions [90, 130,
135]. Importantly, a novel Wnt/b-catenin signalling inhibitor, AV65,
has been reported to reduce the b-catenin expression and inhibit the
proliferation of IM-resistant and hypoxia-adapted CML cells [130]. It
has also been noted that a combination of AV65 plus IM induced syn-
ergistic anti-proliferative effects on CML cells [130]. Moreover, the
targeting of glyoxalase-1, which catalyses the detoxification of a
highly cytotoxic by-product of glycolysis termed methylglyoxal, using
a specific inhibitor termed S-p-bromobenzylglutathione cyclopentyl
diester was also more effective at inducing the apoptotic effects on
TKI-resistant, quiescent and hypoxia-adapted BCR-ABL leukaemic
cells with acquired stem cell-like features than on parental leukaemic
cell lines in vitro and in vivo [90]. In the same way, the inhibition of
autophagy by using pharmacological agent such as bafilomycin A1 or
3-methyladenine as well as chloroquine which can act as an inhibitor
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of late-stage autophagy has been observed to potentiate the cytotoxic
effects induced by TKIs such as IM or dasatinib on CML cells, includ-
ing more primitive CML-LSCs, in vitro and in vivo [135].
Overall, these recent studies have underlined the critical role of
hypoxia and H1F-1a, altered metabolic pathways and autophagy for
the survival and treatment resistance of LSCs in the hypoxic microen-
vironment of BM, including in the insensitivity of BCR-ABL+ CML-
LSCs to TKIs that target the bulk mass of proliferative leukaemic cells.
Thus, the combined inhibition of H1F-1a, glycolysis and autophagy
constitutes promising approaches to kill the LSC subpopulation in the
hypoxic endosteal niche of BM that may be responsible for treatment
resistance and disease relapse, and thereby improve the efficacy of
current therapies against aggressive and recurrent leukaemias.
Functions of hypoxia and HIFs in the
development of glioblastoma
multiforme and targeted therapies
Glioblastomas are among the most frequent, aggressive and lethal
brain tumours because their rapid progression to locally invasive dis-
ease states and development of different molecular mechanisms of
resistance by tumour cells to current radiation therapies and chemo-
therapies with DNA-alkylating agents such as temozolomide, nitro-
soureas and/or cisplatin [82, 136–138]. In this regard, recent
accumulating lines of evidence have revealed that a subpopulation of
glioma stem cells (GSCs), also designated as glioma-initiating cells,
expressing stem cell-like markers such as CD133, nestin, CD44, Oli-
go-2, Oct-3/4, Sox-2, Nanog, Musashi and/or Bmi-1 and endowed
with high self-renewal and tumourigenic capacities may be responsi-
ble for driving glioblastoma multiforme (GBM) development, local
invasion, resistance to current therapeutic treatment and disease
recurrence [82, 126, 127, 139–141].
Glioblastoma multiforme is a heterogeneous disease and encom-
passes distinct molecular subtypes characterized by specific gene
signatures [82, 142–144]. In general, GBMs are highly vascularized
tumours and exhibit intratumoral heterogeneity, including in pheno-
typic features of tumour cells found within normoxic and hypoxic
regions [1, 82, 127]. Particularly, GBM pathogenesis typically impli-
cates an increased expression of many growth factors, cytokines and
chemokines and their cognate receptors in tumour cells that cooper-
ate to their malignant transformation and acquisition of more aggres-
sive phenotypes and tumour neoangiogenesis during progression to
locally invasive GBMs [82]. The changes within local tumour microen-
vironment of GBM cells, including hypoxia also may induce the
enhanced expression of HIF-1a, HIF-2a and stem cell-like markers
such as pluripotency-associated gene products Oct-3/4, Sox-2,
Nanog and Myc that promote their stem cell-like properties and gain
of a more aggressive behaviour [126, 127, 145, 146]. Importantly,
immunohistochemical analyses have indicated that HIF-1a and HIF-
2a and their target genes, including glycolytic enzymes and VEGF are
frequently overexpressed in tumour cells in hypoxic zones closest to
areas of necrosis, which demarcate surrounding regions of tumour
angiogenesis, during GBM development [1, 2, 127]. Moreover, it has
been noticed that an enhanced expression of HIF-1a and HIF-2a in
tumour cells was strongly correlated with tumour grade and vascular-
ity of GBM tissue specimens [1]. These data suggest that HIF-1a and
HIF-2a can contribute to the rapid re-oxygenation of hypoxic zones of
GBMs that may be mediated in part through the enhanced expression
of pro-angiogenic factors such as VEGF (Fig. 2). In this regard, it has
also been observed that GSCs are enriched in a region, designated as
vascular niche around tumour vessels as well as in a hypoxic niche
localized near necrotic areas associated with restricted oxygen and
nutrients [82, 139–141]. It has also been shown that HIF-2a can play
key roles in GSCs found within perinecrotic/hypoxic niche by inducing
enhanced expression of specific tumour stem cell signature genes,
including mastermind-like protein 3 (Notch pathway), nuclear factor
of activated T cells 2 (calcineurin pathway) and aspartate b-hydroxy-
lase domain-containing protein 2 that are associated with a poor
prognosis of GBM patients [147]. In the same way, the enhanced
expression of HIF-1a in CD133+ GSCs from human glioma specimens
propagated under hypoxia (1% oxygen) also promoted their
self-renewal capacity, inhibited their differentiation and led to the
expansion of GSCs expressing CXCR4, CD44low and A2B5 surface
markers [148].
Interestingly, it have also been observed that GSCs expressing
stem cell-like markers CD133, Oligo-2, Oct-3/4, Sox-2, Nanog, Mus-
ashi and Bmi-1 from human glioblastoma biopsy specimens xeno-
grafted into brains of immunocompromised mice secreted high levels
of VEGF, which were promoted under hypoxia, and generated highly
vascularized tumours with areas of necrosis and haemorrhage [149].
In contrast, CD133# tumour cells only formed a few secondary
tumours that were poorly vascularized [149]. In the same way, the
data of immunohistochemical analyses have indicated that HIF-2a
was co-expressed with CD133 stem cell-like marker in GBM tissue
specimens, and associated with a poor survival of glioma patients
[127]. It has also been noted that HIF-2a and its target genes, includ-
ing Oct-3/4, SerpinB9, GLUT-1 and VEGF were preferentially
expressed in CD133+ GSCs from glioblastoma surgical biopsy speci-
mens or xenografts derived from brain tumour specimens as com-
pared with CD133# tumour cells under hypoxic conditions [127].
In addition, the maintenance of GSCs and their differentiated
progenies in normoxic and hypoxic regions within tumours also
requires the interplay of different intrinsic and extrinsic factors that
govern the embryonic brain tumour development [41, 82, 127, 150,
151]. Particularly, the sustained activation of different growth factor
cascades, including EGFR, constitutively activated EGFRvIII mutant
and IGF-1/IGF-1R may stimulate PI3K/Akt/mTOR signalling elements
that in turn induce the stabilization and/or translation of HIF-1a and
HIF-2a proteins in GSCs and their progenies and angiogenic switch
[82, 137, 152]. Moreover, GBM development is typically characterized
by a high incidence of PTEN mutation in late stage of tumorigenesis
[41, 82, 137, 153]. PTEN inactivation may promote the sustained acti-
vation of PI3K/Akt pathway that in turn can induce HIF-1a stabilization
and transcriptional expression of its target genes, and thereby
contribute to the survival of GBM cells under normoxic and hypoxic
conditions [41, 82, 137, 153]. For instance, it has been observed that
the ectopic overexpression of wild-type PTEN in the human U373
glioblastoma-derived cell line lacking functional PTEN reduced IGF-1-
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and hypoxia-induced Akt activation and consequently the HIF-1a sta-
bilization and expression of its target gene products, including glyco-
lytic enzymes, PGK-1 and PFK, COX-1 and VEGF [41].
Of therapeutic interest, numerous studies have also indicated the
benefit to target HIF signalling network, including growth factors impli-
cated in the regulation of HIF activity, altered metabolic pathways and
angiogenic factors to kill GSCs and their differentiated progenies under
normoxic and hypoxic conditions, and thereby prevent GBM progres-
sion to locally invasive disease state [108, 127, 148, 154, 155]. For
instance, it has been observed that the targeting of HIF-1a or HIF-2a
by shRNA in CD133+ GSCs from a patient’s glioblastoma specimen
inhibited their neurosphere-forming ability and proliferation, induced
the caspase-dependent apoptotic effect in vitro and attenuated their
tumour-initiating potential in vivo [127, 148]. Moreover, the down-reg-
ulation of histone methyltransferase mixed-lineage leukaemia 1
(MLL1) by shRNA in GBM cells, which is induced under hypoxic con-
dition, was also effective at reducing the expression of HIF-2a protein
and its target genes, including VEGF and inhibiting the self-renewal,
growth and tumourigenicity of GSCs [108]. The targeting of VEGF
using neutralizing mAb, bevacizumab was also effective at inhibiting
tumour growth of xenografts derived from CD133+ glioma-initiating
cells or U87 glioma cells by decreasing the number of self-renewing
and vessel-associated CD133+/nestin+ tumour cells [141, 149].
In addition, the down-regulation of key regulators of autophagy
such as DNA-damage regulated autophagy modulator protein 1
(DRAM1) or p62 encoded by sequestosome 1 (SQSTM1) by shRNA
in GSCs has also been shown to impair autophagy, reduce metabolic
energy, including ATP and lactate levels, and inhibit the migration and
invasion of GSCs [154]. Moreover, the data from a randomized and
double-blind, placebo-controlled trial carried out with 30 patients with
surgically confirmed GBMs have also indicated that the autophagy
inhibitor, chloroquine improved the anticarcinogenic efficacy induced
by conventional radiotherapy and chemotherapy and median survival
of GBM patients [156].
Collectively, these observations suggest that HIF-induced–
enhanced glycolysis and VEGF expression as well as altered auto-
phagy in GSCs may represent selective adaptations that are necessary
for their survival under stressful conditions, including in a hypoxic
microenvironment and nutrient deprivation, rapid tumour neovascu-
larization and re-oxygenation and progression to locally invasive dis-
ease states. The development of new combination therapies
consisting to target HIF signalling network and altered metabolic
pathways in GSCs and their progenies as well as the components of
their vascular and hypoxic niches represents new therapeutic strate-
gies to improve the efficacy of current therapies and counteract the
progression to highly invasive and lethal GBMs.
Functions of hypoxia and HIFs in the
development of melanoma and
targeted therapies
Malignant cutaneous melanoma is the most aggressive and lethal
form of skin cancer with a poor prognosis for patients with advanced
disease [157–160]. Although surgical tumour excision of early melan-
ocytic lesions is associated with high cure rates, the rapid progres-
sion to locally invasive and metastatic melanomas that are resistant
to current radiotherapies and chemotherapies usually led to disease
relapse and the death of melanoma patients [157–160]. A growing
body of evidence has indicated that intertumoral and intratumoral het-
erogeneity of melanomas may be due in part to the differences
between melanoma stem/progenitor cells at the origin of a particular
melanoma subtype as well as the changes in their number and pheno-
typic and functional features during melanoma progression and after
treatment initiation. In support with this, a subset of melanoma stem/
progenitor cells expressing stem cell-like markers such as CD133,
nestin, neural crest nerve growth factor receptor CD271, Oct-3/4, Na-
nog, multi-drug resistance protein-1 (MDR1), ABCG2 and/or ABCB5
has been isolated from human primary and metastatic melanoma
specimens or melanoma cell lines [83, 161–165]. Tumourigenic mel-
anoma stem/progenitor cells with high self-renewal capacity and
aberrant differentiation potential were able to generate melanomas
when transplanted into human skin or bone or animal models with
histopathological features resembling human melanomas [161–164].
Importantly, high expression levels of HIF-1a, HIF-2a and their
target genes such as VEGF, have also been detected in melanoma
cells in up to 80% cases of primary and metastatic melanoma speci-
mens from patients, and more particularly at the margin of necrotic
areas of tumours, and associated with melanoma progression as well
as a poor prognosis of patients [1, 166–169]. Moreover, a nuclear
staining for pluripotency-associated transcription factor Oct-3/4 was
also seen in a small subset of melanoma cells, and particularly in
hypoxic cancer cells near necrotic areas within primary melanomas in
vertical growth phase or metastatic melanoma tissue specimens
[112]. It has also been shown that the exposure of melanoma cell
lines to hypoxia up-regulated expression levels of HIF-1a and HIF-2a
and their target genes including Oct-3/4, Nanog, Nodal, connective
tissue growth factor (CTGF), snail-1 and VEGF that in turn promoted
their self-renewal ability, tumourigenicity, metastatic potential and
resistance to current chemotherapeutic drugs such as temozolomide
and cisplatin as well as angiogenic switch [112, 170–172]. The ecto-
pic overexpression of Oct-3/4 in melanoma cell lines was also effec-
tive to enhance their expression of stem cell-like markers such as
CD271, MDR1, ABCG2, ABCB5, Kruppel-like factor 4 (KLF4) and
Nanog and self-renewal capacity [112].
In addition to hypoxia, enhanced expression and/or stability of
HIFs in melanoma cells may also be induced by stress signals such
as heat shock and reactive oxygen species (ROS), microphthalmia-
associated transcription factor (MITF) and stimulation of oncogenic
growth factor cascades under normoxic and hypoxic conditions [173
–180]. The tumourigenic signalling elements involved in the modula-
tion of HIF activity include Notch, endothelins (ETs)/ETB receptor and
constitutively activated B-Raf or N-Raf mutant that may contribute to
the sustained activation of PI3K/Akt, MAPKs and/or NF-jB [173–
180]. Particularly, it has been shown that B-RafV600E mutant may
induce an increase in HIF-1a expression under normoxic and hypoxic
conditions [177]. It has also been noticed that the expression of a
HIF-1a785 isoform lacking a part of the oxygen regulation domain and
which is more stable than full-length HIF-1a under high oxygen
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tension, was also induced by 12V-H-Ras, hyperthermia, serum, EGF,
phorbol 12-myristate 13-acetate (PMA), heat and oxidative stresses
in melanoma cell lines under normoxic conditions [178, 181].
Moreover, tumour hypoxia has also been associated with enhanced
expression of HIFs, lactate dehydrogenase 5 and autophagy-related
proteins, including beclin-1 and light chain 3A (LC3A), in hypoxic mel-
anoma cells that may promote anaerobic glycolysis and extensive
autophagy activity and contribute to their survival under oxygen and
nutrient deprivation [169]. On the other hand, high level of HIF-1a
has also been detected in melanoma cells expressing melanoma
antigen recognized by T cells-1 MART-1+ found in perivascular
regions within tumour as well as MART-1# non-haematopoietic mela-
noma-associated stromal cells, including CD146+ pericytes associ-
ated with CD31+ endothelial cells and Sca-1+ stromal cells in a mouse
model of melanoma [182]. This suggests that stromal cells and
melanoma cells, which can form functional vessel-like structures by
vasculogenic mimicry, can cooperate for tumour vascularization sup-
porting the interest to co-target these cells to counteract melanoma
development.
Novel therapeutic strategies against aggressive and metastatic
melanomas have also been investigated that consist to the molecular
targeting of HIFs and/or their target gene products including pro-
angiogenic factors such as VEGF, EMT programme- and altered
metabolism-associated molecules in melanoma stem/progenitor cells
and their progenies to counteract melanoma progression and metas-
tases and reversing treatment resistance [23, 33, 172, 176, 179, 180,
183–188]. For instance, the ETBR blockage using a pharmacological
antagonist, A-192621 resulted in a decrease in HIF-1a and HIF-2a
stability concomitant with an increase in prolyl hydroxylase domain
protein 2 level that was accompanied by an inhibition of tumour
growth and angiogenesis of human M10 melanoma cell-derived xeno-
grafts in nude mice [176]. It has also been shown that the treatment
of human A2058 melanoma cells with a small-molecule STAT3 inhibi-
tor, CPA-7 was effective at inhibiting the expression of HIF-1a and
VEGF in vitro and tumour growth and angiogenesis of human A2058
melanoma tumours in vivo [33].
Together these studies have indicated that the enhanced expres-
sion of HIFs and their target gene products and altered metabolism in
melanoma cells during disease progression may promote their malig-
nant reprogramming, including their acquisition of stem cell-like
properties and more aggressive and metastatic phenotypes and
angiogenic switch. The targeting of HIF signalling elements that are
involved in the survival of melanoma-initiating cells under hypoxic
and stressful conditions represents new promising strategies to
prevent melanoma development and treatment resistance.
Functions of hypoxia and HIFs in the
development of prostate cancer and
metastases
Prostate cancer (PC) is among the most common malignancies in
men [160, 189, 190]. Metastatic PCs still represent the second lead-
ing cause of cancer-related death [160, 189, 190]. Although important
advances have led to an earlier diagnosis and effective therapeutic
intervention by prostatectomy and/or radiation therapy for patients
with localized PCs, the disease progression to locally invasive and
metastatic castration-resistant prostate cancers (CRPCs) is generally
associated with treatment resistance and disease relapse [160, 189,
190]. Moreover, current anti-hormonal treatments and first-line
docetaxel-based chemotherapies against metastatic CRPCs are only
palliative and culminate in the death of most patients after about
12–19 months [160, 189, 190]. Importantly, accumulating lines of
experimental evidence have indicated that PC- and metastasis-initiat-
ing cells expressing stem cell-like markers such as CD133+, CD44high,
ALDHhigh, ABCG2+ and/or CXCR4high and endowed with a high
self-renewal ability can play critical functions for PC progression,
metastases and resistance to current clinical therapies [45, 53, 95,
97, 191–194].
Recent studies have also revealed that an increase in expression
levels and transcriptional activity of HIF-1a and HIF-2a frequently
occur in PC cells during primary PC progression and bone metasta-
ses and is associated with treatment resistance and a poor outcome
of patients [1, 4, 9, 13, 101, 195–200]. More specifically, the
sustained activation of EGF and TGF-a/EGFR and TGF-b/TGF-bR cas-
cades as well as the down-regulation or loss of PTEN and enhanced
levels of inflammatory cytokines such as TNF-a during PC progres-
sion and after treatment initiation may result in the stimulation of
PI3K/Akt/mTOR, NF-jB and/or MAPK signalling elements in PC cells
[28, 34, 35, 42, 119, 201]. These tumourigenic pathways in turn may
induce the expression, stabilization and nuclear translocation of HIF-
1a and/or HIF-2a in PC cells under normoxic and hypoxic conditions
and contribute to their gain of a more malignant behaviour [28, 34,
35, 42, 119, 201–203]. Moreover, it has been observed that the
changes in the tumour microenvironment of PC cells, including the
prevalence of hypoxic zones in primary PCs, and more particularly at
the invasive front, may induce HIF-1a and HIF-2a and the reprogram-
ming of PC cells to re-express high levels of some stemness gene
products such as CD44, Oct-3/4 and Nanog (Figs 2 and 3) [4]. The
maintenance of PC cell lines under hypoxic conditions has also been
observed to result in their acquisition of more aggressive phenotypes
and enrichment of hypoxic cancer cells with stem cell-like features
and expressing high levels of drug resistance-associated molecules,
such as multi-drug transporter, ABCG2 and anti-apoptotic factor,
Bcl-xL [8, 14, 48, 57, 111, 204]. For instance, it has been observed
that the culture of human androgen-independent (AI) and metastatic
PC3 and DU145 prostatic cancer cells under low oxygen level (7% or
1% O2) was accompanied by up-regulation of HIF-1a and HIF-2a
expression and enhanced colony formation efficacy of these hypoxic
PC cells as compared with normoxic conditions (20% O2) [14]. More-
over, the number of SP cells and PC3 and DU145 cells expressing
stem cell-like markers such as CD44high, ABCG2high, Oct-3/4 and
Nanog and endowed with high prostasphere-forming ability detected
in PC3 and DU145 cell lines was also increased under hypoxia [14].
On the other hand, the conditioned medium from PC-associated
fibroblasts activated by TGF-b1 or IL-6 has also been observed to
promote in a paracrine manner the induction of EMT programme in
PC3 cells and their gain of stem cell-like features, including high
prostasphere-forming capacity and migratory ability by inducing
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inflammatory factors such as cycloxygenase-2 (COX-2), NF-jB and
HIF-1a [205, 206].
In addition, some studies have also indicated that the metastases
of PC cells at distant sites, including bones, may occur early during
disease progression, and the persistence of dormant PC cells homing
at bones, may represent a determinant factor associated with the
bone tumour formation and disease relapse after treatment initiation
(Fig. 4) [53, 207–209]. Some similarities between the molecular
mechanisms that govern the specific engraftment and homing of
HSCs to bones are also observed for PC cells that preferentially
migrate and adhere to bones. More specifically, the chemoattractant
gradient formed by SDF-1 molecules released from BM-resident
endothelial cells and stromal cells appears to provide critical func-
tions for the specific dissemination, engraftment, migration through
matrix and homing of CXCR4+ PC cells to BM as observed for LT-
HSCs (Fig. 4) [53, 208, 210–214]. Moreover, it has been shown that
metastatic PC cells homing at BM can compete with resident HSCs to
occupy the most hypoxic endosteal niche formed by osteoblasts
[208, 211]. In this regard, numerous growth factors and cytokines,
including SDF-1, EGF, sonic hedgehog (SHH), TGF-b1, bone morpho-
genic proteins (BMPs) and MIC-1 released by metastatic PC cells,
stromal fibroblasts, osteoblasts, osteoclasts and HSC/HPCs in BM
microenvironment may contribute to the regulation of dormancy
phenomenon of PC cells in hypoxic endosteal niche and promote
their re-activation and formation of macrometastases and osteoblas-
tic and/or osteolytic lesions under specific microenvironmental condi-
tions [53, 194, 209, 215–217]. More particularly, it has been shown
that BMP-7 secreted by BM-resident stromal cells may activate BMP
receptor 2-induced p38/N-myc downstream-regulated gene 1 axis
and cause a reversible senescence state in PC stem cell-like cells
suggesting that BMP-7 can play a critical role in the regulation of
their dormancy and hibernation at bones [216]. Moreover, it has also
been observed that CXCR4 was highly up-regulated in both meta-
static and AI PC3 and DU145 cells grown under prostasphere-form-
ing conditions compared with monolayer growth conditions as well
as in the CD133+/CD44+ PC stem/progenitor cell subpopulation from
these PC cell lines relative to the CD133#/CD44# PC fraction [194].
The isolated CXCR4+ or CD133+/CD44+/CXCR4+ PC3 and DU145
stem/progenitor cell subpopulation also displayed higher prosta-
sphere- and colony-forming abilities in vitro and tumourigenicity in
vivo than CXCR4# or CD133#/CD44# PC cells [194]. It has also been
observed that the stimulation of PC3 and DU145 cells with exogenous
SDF-1 activated PI3K/Akt-induced inhibition of forkhead (FOXO3A)
transcription factor pathway and led to an enrichment of CD133+/
CD44+ PC cell number (Fig. 3) [194]. These data suggest that the
stimulation of CD133+/CD44+/CXCR4+ PC stem/progenitor cells by
SDF-1 can induce the PI3K/Akt cascade that in turn plays critical
functions for their high self-renewal and skeletal metastases. Future
investigations are, however, necessary to further establish the func-
tions of the hypoxic microenvironment in the BM endosteal niche and
HIFs in controlling the dormancy phenomenon, self-renewal, survival
and formation of well-established metastases by metastasis-initiating
PC cells as well as their interactive cross-talks with other growth
factor pathways including SDF-1/CXCR4 axis and TGF-b family
members.
Novel therapies by targeting HIFs and altered
metabolic pathways in PC stem/progenitor cells
and their differentiated progenies
Numerous studies have been carried out to establish the therapeutic
benefit to down-regulate expression levels, stability and/or transcrip-
tional activity of HIF-1a and/or HIF-2a by RNA interference or using
pharmacological inhibitors of HIFs to eradicate PC cells [8, 54, 57–
61, 202, 206, 218–222]. Among the pharmacological agents targeting
HIF signalling network, there are specific inhibitors of HIFs (YC-1,
P276-00, P3155, JG243, JG244 and NSC-134754), zinc, cyclin-
dependent kinase inhibitor (P276-00), histone deacetylases (panobi-
nostat) and mTOR complex 1 (everolimus) (Table 1) [8, 54, 57–61,
206, 218–222]. The results have indicated that the targeting of HIF
pathway with these inhibitory agents induced the anti-proliferative,
anti-invasive, anti-metastatic and/or apoptotic effects on PC cells
under normoxic and hypoxic conditions and improved the cytotoxic
and anti-angiogenic effects induced by irradiation and chemotherapy
in vitro and in vivo [8, 54, 57–61, 202, 206, 218, 219, 221, 222]. For
instance, it has been reported that the prostasphere-forming capacity
of PC3 cells stimulated by the conditioned medium from activated fi-
broblasts as well as their tumour growth and metastatic spread in
nude mice were significantly inhibited by shRNA targeting the pro-
inflammatory signature including COX-2, NF-jB or HIF-1a [206]. New
G-rich ODNs termed JG243 and JG244, which form an intramolecular
parallel G-quartet structure, have also been observed to selectively
interact with HIF-1a and HIF-2a proteins and induce their proteaso-
mal degradation [54]. JG243 or JG244 mixed with a solution of poly-
ethylenimine (PEI) was also effective at inhibiting the expression of
HIF-regulated proteins such as VEGF, Bcl-2 and Bcl-xL and dramati-
cally suppressing the growth of human PC3 tumour xenografts in
nude mice [54]. Moreover, a combination of JG244/PEI plus a G-rich
ODN directed against the phosphorylated STAT-3 protein termed
T40214/PEI also inhibited the growth and induced the apoptotic effect
on human DU145 prostate tumours and transgenic adenocarcinoma
of mouse prostate (TRAMP)-C2 model in vivo as compared with
drugs alone [218]. Interestingly, it has also been observed that the
treatment of PC3 cells with anthracyclines, doxorubicin or daunorubi-
cin was effective at suppressing the HIF-1a transcriptional activity
and its target genes, GLUT-1 and VEGF [58]. Also, treatment of
severe combined immunodeficient (SCID) mice bearing PC3 cell-
derived tumour xenografts with doxorubicin or daunorubicin signifi-
cantly reduced the tumour growth, recruitment of BM-derived cells
and angiogenesis as compared with untreated mice [58]. Another
study using doxorubicin encapsulated in pegylated liposomes has
also indicated that this liposomal formulation Caelyx® was effective at
improving the cytotoxic effects induced by radiation treatment on
hypoxic tumours derived from androgen-sensitive CWR22 cells
[201]. These data suggest that anthracyclines could be used, either
alone or in combination therapy with current chemotherapeutic drug
docetaxel, to inhibit the HIF-1a activity and induce the anti-angiogenic
effects in hypoxic prostate tumours.
In considering the fact that the major cause of disease relapse
of PC patients is caused by a rapid spread of PC cells to distant
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sites, including bones, and their homing under a dormant state, the
targeting of metastasis-initiating PC cells is highly necessary to
improve the efficacy of current cancer treatments and prevent
severe and intractable pain associated with osteoblastic and osteo-
lytic bone lesions (Fig. 4). Importantly, it has been observed that
the enhanced expression of CXCR4 in PC cells, which may be
induced under hypoxic conditions, was associated with a high risk
of metastases at distant sites including bones and poor outcome of
cancer patients [223]. Of therapeutic interest, it has also been
reported that the targeting of CXCR4 using antagonist AMD3100 or
anti-CXCR4 antibody was effective at decreasing the CD133+/CD44+
PC subpopulation, but did not significantly affect the CD133#/
CD44# PC fraction within the total mass of PC3 or DU145 cells
[194]. An opposed effect, however, was seen with docetaxel or
5-fluorouracil treatment which induced an enrichment of CD133+/
CD44+ PC subpopulation [194]. Importantly, a combination of
CXCR4 antagonist AMD3100 or Akt inhibitor NVP-BEZ235, which
targets CD133+/CD44+/CXCR4+ DU145 stem/progenitor cells plus
docetaxel was also more effective at inducing the tumour growth
inhibitory effect on DU145 cell xenografts in non-obese diabetic
(NOD)/SCID mice and preventing the tumour re-growth after treat-
ment cessation as compared with individual drugs [194]. Moreover,
the inhibition of SDF-1/CXCR-4 axis in metastatic PC3 cells using
anti-CXCR4 monoclonal antibody (mAb) or CXCR4 antagonist,
AMD3011 has been observed to impair their homing at the hypoxic
endosteal niche in BM and inhibit bone tumour formation [208, 211,
224]. These results underline great interest to target CXCR4 and Akt
in PC- and metastasis-initiating cells for improving current therapies
and preventing disease relapse.
On the other hand, numerous studies have also revealed the pos-
sibility to inhibit lipogenesis, glycolysis and/or autophagy to restraint
the energy supply required for a high proliferation rate and survival of
metastatic and hypoxic PC cells including PC stem/progenitor cells
[48, 95, 225–234]. Particularly, the data from global transcriptional
profiling have revealed that the activity of monoacylglycerol lipase
(MAGL), which plays a major role in lipogenesis in metastatic PC cells
by converting monoglycerides to free fatty acids, was higher in AI and
metastatic PC3 and DU145 cells relative to androgen-dependent
LNCaP cells and associated with a gene signature that correlated with
the EMT programme and stem cell-like properties of PC cells [234].
Also, the treatment of PC3 and DU145 cells with a selective inhibitor
JZL184 of MAGL activity was effective at reducing their migration,
invasion and survival in vitro and inhibiting the tumour growth of PC3
cell xenografts in SCID mice [234]. In addition, the results from a
phase I trial have also indicated that the administration of a synthetic
glucose analogue, 2-deoxy-D-glucose (2-DG) to PC patients had no
major secondary effects and five of eight patients assessed with flu-
orodeoxyglucose (18F)-positron emission tomography (FDG-PET)
scanning exhibited a decreased FDG uptake by day two of therapy
[228]. It has however been noted that a treatment with 2-DG may be
associated with enhanced autophagy in PC cells which may contribute
to their 2-DG resistance [228]. Of therapeutic interest, the combina-
tion of 2-DG with an anti-diabetic compound including pioglitazone or
metformin, which acts at least in part as an inhibitor of 2-DG-induced
autophagy, has been observed to be more effective at inducing the
apoptotic effects on metastatic LNCaP, PC3 and DU145 cells than
drugs alone [229, 232].
Collectively, these recent studies have revealed that the adaptation
of AI and metastatic PC stem/progenitor cells and their differentiated
progenies to hypoxia and nutrient deprivation through the induction
of HIFs, glycolytic pathways and autophagy may result in their
enhanced expression of pluripotency-associated molecules and
acquisition of a more aggressive behaviour during PC progression
and bone metastases. Novel inhibitors of HIF-1a and/or HIF-2a and
altered energy metabolism have been shown to be effective at induc-
ing cytotoxic effects on hypoxic PC cells. Thus, these observations
support therapeutic interest to further investigate these pharmacolog-
ical agents for eradicating hypoxic PC- and metastasis-initiating cells
endowed with stem cell-like properties and reversing the resistance
to current anti-hormonal treatments, radiation therapy and docetaxel-
based chemotherapies.
Functions of hypoxia and HIFs in the
development of breast cancer and
metastases
Breast cancer encompasses a heterogenous group of disease charac-
terized by an accumulation of different genetic and epigenetic altera-
tions occurring in the basal and/or luminal breast epithelial cells in
the mammary gland [235, 236]. Although breast tumour resection
may lead to a high survival rate for breast cancer patients diagnosed
at early stages, locally advanced and highly invasive and metastatic
breast cancer subtypes are generally refractory to current anti-hor-
monal treatments, targeted therapies against erbB2/HER2, irradiation
and chemotherapies [160, 237, 238]. The heterogeneous nature of
breast cancers may be due in part to the implication of different
subpopulations of breast cancer stem cells (BCSCs) and their early
progenitors that are responsible for tumour development and metas-
tases at distant sites [73–80, 88, 239]. More specifically, highly tumo-
urigenic BCSCs and their early progenitors endowed with a high
self-renewal potential and which can express different stem cell-like
markers such as CD44+, CD24#/low, epithelial-specific antigen (ESA+),
CD133+, ALDH1high, Oct-3/4, Nanog, Kruppel-like factor (KLF-4) and/
or CXCR4high have been detected and isolated from breast tumour
specimens from patients and breast cancer cell lines [73–80, 88,
239]. Moreover, gene expression profiling and gene set enrichment
analyses have revealed that CD44+/CD24#/low BCSC subpopulation
showed increased expression of genes involved in TGF-b, TNF-a,
interferon and NF-jB pathways that can contribute to the induction of
the EMT programme in BCSCs and promote their mammosphere-
forming ability and tumourigenicity [239–245]. Importantly, BCSCs
expressing high levels of multi-drug transporters such as brain can-
cer resistance protein (BCRP)/ABCG2high, DNA repair enzymes and
free radical scavengers and which can survive under oxygen and
nutrient deprivation have been shown to be involved in the resistance
to anti-hormonal and anti-angiogenic treatments, radiation and
chemotherapies [45, 74, 79, 96, 241, 246–250].
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Recent lines of experimental evidence have also indicated that
enhanced expression levels of HIFs in BCSCs and their differentiated
progenies in hypoxic intratumoral regions within poorly vascularized
tumours and hypoxic BM microenvironment as well as the induction
of the EMT programme may result in their acquisition of stem cell-like
features, a high rate of glycolytic metabolism and more aggressive
and invasive phenotypes as well as enhanced tumour angiogenesis
during breast cancer progression [4, 15, 16, 50, 74, 75, 77, 79, 88,
251]. In support of this, a direct relationship between the co-expres-
sion of HIF-1a and the CD44+/CD24#/low phenotype has been
observed by immunohistochemical analyses of 253 samples of breast
ductal carcinoma from patients, and associated with a worse progno-
sis of breast cancer patients [50]. Moreover, it has been observed
that the expression levels of Jagged2 and nuclear Notch intracellular
domain were up-regulated in hypoxic regions at the invasive front of
breast tumour tissues, and the enhanced expression of Jagged2 in
breast cancer cells cultured under hypoxia led to the activation of
Notch pathway and induction of the EMT programme [15]. An
enhanced activity of HIF-1a under hypoxia has also been observed to
result in the up-regulated expression of TGF-b superfamily member,
Nodal through the activated Notch pathway in breast cancer cells that
in turn contributed to their invasion and metastatic spread [16].
Importantly, CD44+/CD24#/low BCSCs expressing high levels of HIF-
1a and mesenchymal markers such as N-cadherin and vimentin, but
low level of E-cadherin, activated Wnt/b-catenin, and PI3K/Akt cas-
cades also displayed higher clonogenic and mammosphere-forming
abilities and tumourigenicity under normoxic and hypoxic conditions
than their differentiated progenies [16, 74, 88]. Interestingly, an expo-
sure of non-adherent human metastatic MDA-MB-231 and BCM2
breast cancer cells to three cycles of hypoxia and re-oxygenation has
also been observed to be accompanied by an enrichment of the
CD44+/CD24#/low/ESA+ BCSC fraction [79]. The CD44+/CD24#/low/
ESA+ BCSC subpopulation from MDA-MB-231 and BCM2 cells also
expressed the EMT markers such as vimentin and snail and
decreased expression of E-cadherin and displayed higher mammo-
sphere-forming capacity, tumourigenicity and metastatic potential to
lungs as compared with parental breast cancer cell lines [79]. In addi-
tion, it has also been observed that activated breast cancer-associated
stromal myofibroblasts may promote the mammosphere formation
and tumourigenicity of breast cancer cells through the release of
SDF-1 that in turn stimulates CD44+/CD24#/low BCSCs expressing
their cognate receptor CXCR4 and angiogenesis [252].
Although the molecular mechanisms that control the high propen-
sity of breast cancer cells to preferentially metastasize to specific tis-
sues and organs, such as lungs and bones remain not precisely
established, it has been shown that hypoxic breast cancer cells within
primary and secondary breast tumours can play critical roles in the
formation of pre-metastatic niches and metastases within the hypoxic
bone microenvironment (Fig. 4) [15, 239, 253–256]. In this matter,
an increased expression level of HIF-1a in primary breast tumour and
metastases has been associated with enhanced rates of metastases
at distant sites and decreased survival of breast cancer patients [1,
10]. More specifically, it has been shown that HIF-1a may induce an
enhanced expression of lysyl oxidase (LOX), lysyl oxidase-like 2
(LOXL2) and LOXL4 in hypoxic breast cancer cells within primary
breast tumour [125, 257]. LOX and LOXLs secreted from hypoxic
breast cancer cells in turn can contribute to the formation of pre-met-
astatic niches at distant tissues such as lungs by inducing the remod-
elling of the extracellular matrix (ECM) through cross-link collagens
and elastins and promoting the recruitment of CD11b+ bone marrow-
derived cells (BMDCs) [125, 257]. Moreover, the enhanced expres-
sion of CXCR4 in breast cancer cells can also play critical roles for
their preferential metastatic spread to distant sites, including bones
and lungs, which secrete high levels of SDF-1 ligand molecules that
act as a chemoattractant gradient (Fig. 4) [256].
In addition, it has also been shown that BCSCs can be involved in
bone metastases within hypoxic bone microenvironment [15, 253–
255]. Particularly, different growth factors and cytokines released by
stromal cells and breast cancer cells, including SDF-1, TGF-b1 and
BMPs as well as the up-regulation of HIF-1a, NF-jB, vascular cell
adhesion molecule-1 (VCAM-1) and Notch in breast cancer cells typi-
cally control their dormancy, survival and self-renewal ability and for-
mation of osteolytic bone metastasis [1, 15, 239, 251, 254, 258–
261]. More specifically, a novel animal model of breast cancer metas-
tasizing to bone has been investigated which consisted of injecting
human CD44+/CD24#/low BCSCs subpopulation from MDA-MB-231
cells in mice previously implanted with human bone in the right or left
dorsal flanks [253]. It has been observed that BCSCs displayed higher
incidence of human bone metastasis relative to the parental breast
cancer cell line, and metastatic bone tissues strongly stained for
CD44, CXCR4 and osteopontin [253]. Moreover, it has also been
noted that the enhanced activity of HIF-1a and TGF-b signalling ele-
ments promoted the EMT programme and up-regulated the expres-
sion levels of CXCR4 and VEGF in breast cancer cells, and thereby
cooperated for their invasion, metastatic spread to bones and skeletal
metastases [239]. In contrast, BMP-2/7 heterodimer, which acts as a
powerful antagonist of TGF-b signalling pathway-induced EMT pro-
gramme and invasiveness of breast cancer cells, strongly reduced the
number of ALDHhigh/CD44high/CD24#/low BCSCs and bone metastases
[262]. Furthermore, the co-culture of CD44+/CD24#/low/ESA+ BCSCs
from MDA231BoM cell line endowed with a strong propensity to
metastasize to bones with immortalized human BM stromal cells HS5
expressing Jagged2 under hypoxia also resulted in the activation of
Notch pathway in BCSCs that promoted their self-renewal potential
[15]. These data suggest that the interactions between stromal cells
and BCSCs in hypoxic BM microenvironment can play important func-
tions for the regulation of their dormant state, self-renewal ability,
bone metastases and treatment resistance. Hence, this underlines
great interest to target hypoxic BCSCs and their supporting host cells
in the hypoxic endosteal niche of BM to prevent skeletal metastases
and disease relapse.
Molecular targeting of HIFs and altered
metabolic pathways in BCSCs and their
differentiated progenies
In view of the fact that BCSCs appear to be principal cancer cells
responsible for breast tumour development and metastases in the
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hypoxic bone microenvironment and are typically more resistant than
their differentiated progenies to anti-hormonal and herceptin treat-
ment, chemotherapy and radiotherapy, their molecular targeting is of
major importance to prevent disease recurrence. In this regard,
numerous studies have indicated that the targeting of HIF and altered
metabolic pathways may eradicate hypoxic breast cancer- and bone
metastasis-initiating cells, reduce tumour angiogenesis and improve
the efficacy of current cancer therapies (Tables 1 and 2) [75, 78, 96,
115, 239, 247, 249, 257, 263–267]. For instance, it has been
observed that the down-regulation of HIF-1a by shRNA or pharmaco-
logical inhibition with 2-methoxyestradiol inhibited the angiogenesis,
reduced the tumour development in bone derived from MDA-MB-231
breast cancer cells intracardially injected in nude mice and increased
the mouse survival [239]. Moreover, the systemic administration of a
combination of specific inhibitors of HIF-1a and TGF-bRI signalling
elements, 2-methoxyestradiol plus SD-208, respectively, that target
breast tumour cells and bone microenvironment, was also more
effective at decreasing bone metastases of MDA-MB-231 breast can-
cer cells and osteoclastic bone resorption and stimulating the forma-
tion of bone mass than individual drugs [239]. On the other hand, the
targeting of CAIX, which is induced by HIF-1a in breast tumour cells
under hypoxia and involved in the pHi regulation also constitutes a
promising therapeutic strategy. It has been observed that inhibition of
CAIX by shRNA or using pharmacological agents such as sulphona-
mide compounds (CAI17, ureido-sulphonamide, U-104) or glycosyl
coumarins (GC-204 and GC-205) induced the apoptosis and reduced
the primary tumour growth and lung metastases of hypoxic breast
cancer cells [115]. Moreover, the inhibition of LOX, which is induced
by HIF-1a in hypoxic breast cancer cells at primary tumours by
shRNA, was also effective at preventing the CD11b+ BMDC recruit-
ment, pre-metastatic niche formation and metastatic growth of MDA-
MB-231 breast cancer cells at lungs in a mouse model [257].
Other therapeutic strategies to eradicate BCSCs and their proge-
nies may also include the targeting of signalling elements such as
hexokinase-2, AMP-activated protein kinase (AMPK), Akt/mTORC1
and/or fatty acid synthase (FASN) that are involved in the regulation
of glycolysis, lipogenesis and/or autophagy induced under hypoxia
and nutrient deprivation (Fig. 3 and Tables 1 and 2) [75, 78, 96, 247,
249, 263–269]. For instance, the treatment of orthotopic tumours
established from hypoxic pre-conditioned MDA-MB-231 cells with
EGFR-targeted nanoparticles (NPs) loaded with paclitaxel and lonid-
amine, which is an inhibitor of hexokinase-2 that catalyses the phos-
phorylation of glucose to yield glucose 6-phosphate during the
glycolysis, has been observed to reduce the tumour growth relative to
NPs loaded with single agent [75]. The anticarcinogenic effects of
NPs were mediated in part through the down-regulation of the expres-
sion levels of HIF-1a, EGFR, P-glycoprotein (P-gp) and SCF [75].
Moreover, a potent and orally bioavailable AMPK activator designated
as OSU-53 has also been observed to reduce the viability and clono-
genic growth of triple-negative MDA-MB-231 and MDA-MB-468
breast cancer cells in vitro and in vivo through the inhibition of mTOR
pathway, lipogenesis and HIF-1a-induced EMT programme [263]. It
has however been noted that OSU-53 induced protective autophagy
in breast cancer cells which could be attenuated by a co-treatment
with an autophagy inhibitor, chloroquine that promoted the in vivo
tumour-suppressive activity of OSU-53 [263]. Also, the inhibition of
FASN activity, which is up-regulated in hypoxic regions of breast
cancer tumours via the activation of Akt and HIF-1a-induced sterol
regulatory element binding protein-1, using cerulenin or PI3K inhibi-
tor LY294002, has also been observed to reverse the resistance of
breast cancer cells to cyclophosphamide under hypoxic conditions
[265]. In the same way, the CD44 knockdown using shRNA lentivirus
particles in BCSCs also induced their differentiation and down-regu-
lated the expression levels of FASN and different stem cell-like mark-
ers, oncogenes and anti-apoptotic factors such as lymphoid
enhancer-binding factor-1 (LEF-1), Myc, EGFR, mucin-1 and Bcl-2
and thereby sensitized these immature cancer cells to the anti-tumor-
al effect induced by doxorubicin [249, 267]. Of particular interest, it
has also been shown that anti-diabetic drug metformin inhibited dif-
ferent metabolic pathways, selectively eradicated BCSCs and acted in
synergy with chemotherapeutic drugs such as doxorubicin and irradi-
ation treatment to kill the total mass of breast cancer cells and
thereby counteract tumour re-growth and disease recurrence [78, 96,
247, 250, 264, 269].
Altogether, these findings have indicated that the enhanced
expression and activity of HIFs and altered metabolism in breast can-
cer cells can promote their malignant reprogramming and gain of
stem cell-like features and thereby contribute to their high self-
renewal ability, survival, tumourigenicity, invasiveness and treatment
resistance under stressful conditions. Hence, novel multi-targeted
therapies directed against HIFs and signalling elements involved in
glycolysis, lipogenesis and autophagy, alone or in combination with
current cancer therapies, constitute new promising approaches to
eradicate total mass of breast cancer cells, including BCSCs, and
thereby prevent their metastatic spread and disease relapse.
Functions of hypoxia and HIFs in the
development of pancreatic cancer and
metastases
Pancreatic ductal adenocarcinomas (PDACs) are extremely aggres-
sive solid tumours, with a poor 5-year survival rate of less than 6%
[160, 270, 271]. The late stage detection and surgical resection of pri-
mary pancreatic tumours result in the disease relapse in most cases
[160, 270, 271]. Moreover, the radiation therapy and first-line gemcit-
abine-based chemotherapeutic treatments of patients with locally
advanced and metastatic PDACs are only palliative and lead to a mod-
est improvement in survival rates [160, 270, 271]. The inefficacy of
current treatments and the poor outcome of PDAC patients are
because of a rapid progression to metastatic disease states and the
development of diverse mechanisms of resistance by pancreatic can-
cer cells to conventional therapies [271–276]. Particularly, it has been
shown that pancreatic cancer stem/progenitor cells expressing stem
cell-like markers such as CD133, CD44 and ABCG2 multi-drug trans-
porter may be more resistant to oxygen and nutrient deprivation, irra-
diation and gemcitabine treatment than the bulk mass of
differentiated pancreatic cancer cells [12, 51, 52, 63, 275].
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Pancreatic ductal adenocarcinomas are among the most hypoxic
of all solid tumours, and are typically characterized by a dense stro-
mal fibrosis also known as desmoplasia and a poor tumour vasculari-
zation that may contribute to restraint procedures of drug delivery
and promote altered metabolic pathways and treatment resistance
[11, 12, 274, 277–279]. In this regard, HIF-1a is up-regulated in
PDACs and can play critical roles for the adaptation of pancreatic can-
cer cells and stromal cells to the hypoxic desmoplastic microenviron-
ment during disease progression, treatment resistance and a poor
outcome for PDAC patients [1, 11, 25, 118, 279–282]. Specifically, a
nuclear HIF-1a staining was seen in about 88% of pancreatic ductal
adenocarcinoma specimens from patients and 43% adjacent stroma,
but in only 16% of the normal pancreatic tissues [11]. Moreover, the
co-expression of HIF-1a and other important oncogenic products and
drug resistance-associated molecules such as K-Ras mutant, which
is detected in up to 75–90% of PDAC cases, hedgehog signalling ele-
ments, CXCR4, toll-like receptor 4 (TLR4), NF-jB p65, survivin, pro-
liferating cell nuclear antigen and VEGF has also been detected in
PDAC tissue specimens from patients and pancreatic cancer cell lines
[118, 280, 282–288]. The expression levels of sonic hedgehog (SHH)
signalling elements, which play critical functions in the desmoplasic
lesion formation were also induced in pancreatic cancer cells under
hypoxic conditions, and the tumour and stromal HIF-1a staining posi-
tively correlated with SHH ligand expression in pancreatic cancer
tumour samples [285]. On the other hand, it has also been shown
that the activation of IGF-1/IGF-1R and SCF/KIT axes in pancreatic
cancer cells may contribute to the induction of HIF-1a through the
stimulation of PI3K/Akt and/or Ras/MEK/ERK pathways and tumour
angiogenesis under normoxic conditions [25, 26].
In addition, the data from immunohistochemical analyses have
indicated that the markers associated with hypoxia (CAIX), pancreatic
cancer stem/progenitor cells (CD44 and CD24) and autophagy (be-
clin-1 and microtubule-associated protein light chain 3 ‘LC3’) were
co-expressed in PDAC tissue specimens from patients [51]. It has
also been observed that the exposure of human MIA-PaCa-2 pancre-
atic cancer cells expressing high levels of CD44 and CD24 stem cell-
like markers to hypoxia and nutrient starvation induced the EMT pro-
gramme and the expression of HIF-1a and autophagy-related genes
[51]. The hypoxia also enhanced the clonogenic capacity, survival,
migration of MIA-PaCa-2 cells and formation of autophagic and acidic
vesicles [51]. In contrast, BxPC-3 pancreatic cancer cells expressing
low levels of stem cell-like markers did not survive under hypoxic and
starvation conditions [51]. In the same way, the expression levels of
CD133, CXCR4 and HIF-1a were also enhanced in the pancreatic can-
cer cell lines under hypoxia as compared with normoxic conditions
and associated with an enhanced invasiveness of CD133+ pancreatic
cancer cells [46, 51]. Importantly, the characterization of a series of
early passage xenografts from 16 patients undergoing surgery for
PDACs and orthotopically grown in nude mice has also revealed that
the presence of hypoxic intratumoral regions was highly correlated
with a rapid tumour growth and spontaneous metastasis formation
[289]. Moreover, the analyses of the HIF-1a expression level in 48
pancreatic cancer tissues from patients who received adjuvant gem-
citabine treatment after pancreatectomy have indicated that HIF-1a
expression was associated with an enhanced neo-microvascularity in
the hypoxic tumour environment and gemcitabine resistance [12]. It
has also been noted that the patients with pancreatic tumours
expressing a strong HIF-1a level had a shorter period until disease
recurrence as compared with those with a weak HIF-1a expression
underlining the importance of also targeting the HIF signalling
network to kill hypoxic pancreatic cancer cells [12].
Novel therapies by targeting HIFs and altered
metabolic pathways in pancreatic stem/
progenitor cells and their differentiated
progenies
New therapeutic strategies by targeting hypoxia and HIF-1a pathways
using RNA interference or specific inhibitory agents in pancreatic can-
cer- and metastasis-initiating cells and their differentiated progenies
for improving current therapies have recently been investigated under
normoxic and hypoxic conditions (Tables 1 and 2) [11, 62–65, 290].
For instance, it has been observed that a hypoxia-activated pro-drug
designated as TH-302, which selectively targets hypoxic regions of
solid tumours in combination with conventional chemotherapeutic
drugs such as gemcitabine-induced greater anti-tumoral effects on
diverse human tumour xenograft models including pancreatic cancer
xenografts than individual drugs without major toxicity [64, 291].
Moreover, it has been reported that a novel fusicoccin derivative
(ISIR-042) was more effective at inducing the growth inhibitory and
cytotoxic effects on hypoxic pancreatic cancer cells than on normoxic
pancreatic cancer cells in vitro and in vivo through a reduction in HIF-
1a and Akt activation [63]. Also, ISIR-042 preferentially induced the
cytotoxic effects on gemcitabine-resistant CD24+/CD44+ pancreatic
cancer stem/progenitor cells from pancreatic cancer cell lines [63]. In
the same way, the inhibition of HIF-1a by a novel selective inhibitor
PX-478 was also effective at potentiating the cytotoxic effects induced
by fractioned radiation treatment, with or without combined treatment
with gemcitabine, on in vitro and in vivo human PANC-1, CFPAC-1 or
SU.86.86 pancreatic cancer models at least in part by reversing
radiation resistance of these hypoxic tumour cells and inhibiting the
pro-angiogenic effect of HIF-1a [11].
Other potential strategies for eradicating pancreatic cancer stem/
progenitor cells and their progenies and reversing treatment resis-
tance, may consist of targeting Ras mutant, EGFR, IGF-1R, PI3K/pAkt
and EMT process-associated molecules, altered metabolic pathways
and autophagy under normoxic or hypoxic conditions [29, 30, 51, 63,
284, 292–296]. For instance, it has been reported that the pharmaco-
logical inhibition of NF-jB activity, which is activated in response to
the enhanced expression and activity of HIF-1a under hypoxia, was
effective at attenuating the induction of the EMT programme and
reversing highly invasive and drug-resistant phenotypes of pancreatic
cancer cells [296]. It has also been noted that the sensitivity of
PANC-1 cells to gemcitabine was reduced under hypoxic conditions
and the targeting of PI3K/Akt pathway using LY294002 plus human
checkpoint kinase 1 (Chk1) inhibitor designated as 7-hydroxystau-
rosporine (UCN-01) partially reversed the gemcitabine resistance
[274]. Of particular interest, the functional inhibition of active Ras by
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S-trans, trans-farnesylthiosalicylic acid was also effective at reducing
HIF-1a expression and promoting anti-proliferative and apoptotic
effects induced by the glycolytic inhibitor 2-DG on pancreatic cancer
cells both in vitro and in vivo [284]. Importantly, the inhibition of
autophagy using 3-methyladenine or monensin also reduced the clo-
nogenicity, spheroid formation, expression of stem cell-like markers
and tumourigenicity of pancreatic cancer cells and induced the apop-
totic effect on pancreatic cancer cells with stem cell-like properties
under hypoxic and starvation conditions [51]. Moreover, the anti-dia-
betic metformin, alone or in combination with difluorinated curcumin
analogue (CDF), was also effective at inhibiting the cell survival, clo-
nogenicity and pancreatosphere-forming ability of pancreatic cancer
cells [276]. Metformin, alone or combined with CDF, also promoted
the pancreatosphere disintegration in both gemcitabine-sensitive and
gemcitabine-resistant pancreatic cancer cells [276].
Altogether, these observations suggest that the up-regulation of
HIF-1a activity, glycolytic metabolism and autophagy may represent
important adaptive processes for the survival of pancreatic cancer
stem/progenitor cells and their progenies under tumour microenvi-
ronmental conditions such as hypoxia and nutrient deficiency. Conse-
quently, the co-targeting of HIF-1a and altered metabolic pathways in
pancreatic cancer- and metastasis-initiating cells and their differenti-
ated progenies represent potential therapeutic strategies to counter-
act rapid PDAC progression, metastatic spread at distant sites,
treatment resistance and disease relapse of this very aggressive and
lethal disease.
Conclusions and perspectives
Taken together, these recent investigations have revealed that the
malignant reprogramming of cancer- and metastasis-initiating cells
and their differentiated progenies may occur within hypoxic intratu-
moral regions at primary neoplasms and hypoxic niches at distant
metastatic sites, including BM, and play critical roles for their acquisi-
tion of aggressive phenotypes and treatment resistance (Fig. 2).
HIF-1a and HIF-2a appear to act as master regulators of adaptation
of cancer stem/progenitor cells and their differentiated progenies to
oxygen and nutrient deprivation by modulating their stem cell-like
properties and metabolic and survival pathways and by activating
tumour-associated stromal cells. Future investigations are, however,
required to more precisely establish the molecular mechanisms at the
basis of specific functions of HIF-1a and HIF-2a, common and unique
gene patterns modulated through these transcription factors and their
cooperative interactions with other growth factors in various human
cancers during disease progression under normoxic and hypoxic
conditions.
The results from some pre-clinical studies have also underlined
great importance of targeting HIFs and altered energy metabolism in
cancer- and metastasis-initiating cells and their progenies as well as
their supporting host cells to overcome the treatment resistance and
thereby prevent disease relapse and the death of cancer patients. Data
from clinical trials have revealed that some anti-angiogenic drugs
may reduce tumour tissue oxygenation and consequently promote
the aggressive behaviour of cancer cells and treatment resistance.
Therefore, the targeting of HIFs represents an attractive adjuvant
cancer therapy to simultaneously eradicate cancer cells and induce
anti-angiogenic effects in highly hypoxic tumours.
We can now envision the possibility of performing expression
analyses of distinct molecular biomarkers associated with hypoxia
and altered metabolic pathways in addition to the current diagnostic
tests to select cancer patients who are likely to respond to cancer
therapies targeting hypoxia including inhibitors of HIF signalling net-
work, glycolysis, lipogenesis and autophagy. These multi-targeted
approaches should be more effective, alone or in combination with
current anti-hormonal treatments, radiotherapy and/or chemotherapy,
against aggressive, metastatic and hypoxic tumours to eradicate total
mass of cancer cells and cure cancer patients.
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